Form 4: RA Capital Management Adjusts Adicet Bio Holdings

RA Capital Management, L.P. has reported a transaction involving the exchange of common stock for a pre-funded warrant in Adicet Bio, Inc.

Summary

• RA Capital Management, L.P., through its affiliate RA Capital Healthcare Fund, L.P., has engaged in a transaction with Adicet Bio, Inc. (ACET).
• On April 27, 2026, the Fund exchanged 250,000 shares of Adicet Bio's Common Stock for a pre-funded warrant.
• This pre-funded warrant is exercisable for up to 250,000 shares of Common Stock at an exercise price of $0.0001 per share.
• The transaction was made pursuant to an Exchange Agreement and no additional consideration was paid for the warrant.
• RA Capital Management, L.P. acts as the investment manager for the Fund.
• The filing indicates that RA Capital Management, L.P. is a 10% owner and director of Adicet Bio, Inc.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a change in the form of ownership rather than a significant new investment or divestment, and does not provide new financial performance data.

Positives

• The exchange for a pre-funded warrant allows RA Capital to maintain its equity interest with minimal immediate cash outlay for the warrant itself.
• The pre-funded warrant is exercisable immediately and has no expiration date, providing flexibility.
• RA Capital Management's continued involvement as a 10% owner and director suggests ongoing strategic interest in Adicet Bio.

Negatives

• The exchange of common stock for a warrant could be interpreted as a strategic shift or a move to manage reporting requirements, though the economic impact is minimal initially.
• The pre-funded warrant has an exercise limitation of 9.99% of outstanding shares, which could cap future direct ownership increases through this instrument.

Risks

• The 9.99% ownership cap on exercising the pre-funded warrant could limit RA Capital's ability to increase its stake beyond this threshold without further transactions.
• Potential future dilution of Adicet Bio's common stock could impact the value of RA Capital's holdings, including those represented by the warrant.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Adicet Bio, Inc. It primarily details a change in beneficial ownership structure by RA Capital Management.

Management Comments

• RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund").
• Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
• The Pre-Funded Warrant has no expiration date and is exercisable immediately.

Industry Context

StockSavvy.ai notes that this Form 4 filing by RA Capital Management, a significant biotech investor, indicates a strategic adjustment in how they hold their stake in Adicet Bio, Inc. Such exchanges for pre-funded warrants are common in the venture capital and biotech investment space, often used to manage ownership reporting thresholds and provide flexibility while maintaining economic exposure.

Related Party Transactions

• The exchange of 250,000 shares of Common Stock for a pre-funded warrant between RA Capital Healthcare Fund, L.P. and Adicet Bio, Inc. is a transaction between an affiliate of a 10% owner and the issuer.

Stakeholder Impact

• Shareholders: The transaction itself does not immediately alter the number of outstanding shares or RA Capital's overall economic interest, thus having a minimal direct impact on other shareholders in the short term. However, the 9.99% exercise cap could influence future voting power or influence.
• Management/Board: RA Capital's continued presence as a director and significant owner, albeit through a warrant, suggests ongoing strategic alignment and oversight.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• RA Capital Management will continue to hold the pre-funded warrant and potentially exercise it, subject to the 9.99% ownership limitation.
• Adicet Bio, Inc. will continue its operations, with RA Capital Management maintaining its role as a significant shareholder and director.

Key Dates

Keywords

Form 4, SEC Filing, RA Capital Management, Adicet Bio, ACET, Beneficial Ownership, Pre-funded Warrant, Common Stock, Insider Trading, Equity Transaction